While both studies highlight the predictive value of Ki-67 and p53, our meta-analysis emphasises the clinical significance of drug-resistant proteins in TNBC therapy, whereas Faur and colleagues focus more on lipid profiles and tumour characteristics across various breast cancer subtypes. The gene discussed is MKI67; the disease is neoplasm.